Is Terns Pharmaceuticals Inc (TERN) overvalued? · $6.12B cap
Terns Pharmaceuticals Inc (TERN) is a biotechnology company listed on NASDAQ.
This page asks whether Terns Pharmaceuticals Inc (TERN) looks expensive on cached numbers — not a short thesis.
Latest reported TERN revenue for 2022-12-31 was $0. Net income was -$60.3M. TERN currently screens at market cap $6.12B.
TERN currently screens at market cap $6.12B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TERN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TERN stock page for the full model, not this heading.
Not investment advice.